Form 8-K - Current report:
SEC Accession No. 0001193125-25-269479
Filing Date
2025-11-06
Accepted
2025-11-06 16:06:45
Documents
14
Period of Report
2025-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d53244d8k.htm   iXBRL 8-K 24141
2 EX-99.1 d53244dex991.htm EX-99.1 66279
6 GRAPHIC g53244g1106235423263.jpg GRAPHIC 6795
  Complete submission text file 0001193125-25-269479.txt   225042

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20251106.xsd EX-101.SCH 2845
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20251106_lab.xml EX-101.LAB 17992
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20251106_pre.xml EX-101.PRE 11257
16 EXTRACTED XBRL INSTANCE DOCUMENT d53244d8k_htm.xml XML 3637
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 251458227
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)